Currently Viewing:
Newsroom
Currently Reading
FDA Grants Indication for Daratumumab Plus Combo in Newly Diagnosed Multiple Myeloma With Transplant
September 27, 2019 – AJMC Staff
Celgene Announces Topline Results for Maintenance Therapy in Acute Myeloid Leukemia
September 17, 2019 – Mary Caffrey
Amgen Posts Updates on Triplet Therapy Using Carfilzomib
September 16, 2019 – AJMC Staff
Key Opinion Leaders Underscore Importance of MRD Testing in Multiple Myeloma
September 13, 2019 – Jaime Rosenberg
AJMC® in the Press, September 13, 2019
September 13, 2019 – AJMC Staff
New Liquid Biopsy Test Found to Identify Patients Who May Respond to Immune Checkpoint Blockade
September 10, 2019 – Matthew Gavidia
Study Explores Brentuximab Vedotin Efficacy in Patients Expressing High CD30 Levels
September 06, 2019 – AJMC Staff
New Treatment Can Benefit Patients With MM Refractory to Multiple Other Therapies
August 30, 2019 – Laura Joszt
Results Point to Annual Assessment of Precursor to Multiple Myeloma
August 22, 2019 – Mary Caffrey

FDA Grants Indication for Daratumumab Plus Combo in Newly Diagnosed Multiple Myeloma With Transplant

AJMC Staff
The new indication is the seventh overall for the therapy, according to Janssen.
FDA has approved daratumumab, sold by Janssen as Darzalex, in combination with bortezomib, thalidomide, and dexamethasone to treat patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant, according to a statement from the company.

Thursday’s approval is based on results from the phase 3 CASSIOPEIA study, which showed that adding daratumumab to the triple therapy combination both before and after transplant brought better responses, including a 53% reduction in the risk of disease progression or death compared with the triple therapy alone.

The approval, the seventh indication for the therapy, came after FDA had granted Janssen Priority Review status for the supplemental Biologics License Application.

Previously, daratumumab was approved in combination with bortezomib, melphalan and prednisone for patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant. And in June, the drug was approved with combination for lenalidomide and dexamethasone to treat newly diagnosed multiple myeloma patients who cannot receive an autologous stem cell transplant.

Daratumumab is also approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for patients with multiple myeloma who have had at least 1 prior therapy. It is approved with pomalidomide and dexamethasone for patients with 2 previous treatments.

“The pivotal phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study ever with daratumumab,” said Philippe Moreau, MD, principal investigator and head of the Hematology Department, University Hospital of Nantes, France. “It’s important that patients get a deep response from their frontline therapy,” he said, and this phase 3 study showed that adding daratumumab to the triple combination both before and after transplant increased response compared with the triple combination alone.

The Multiple Myeloma Research Foundation’s Paul Giusti, president and CEO, praised the milestone. “We are thrilled that newly diagnosed patients with multiple myeloma and their doctors have a new option with this combination,” he said.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up